[Department of Error] Department of Error

August 1, 2015

The Lancet 386, 9993 (2015)

Moskowitz CH, Nademanee A, Masszi T, et al, for the AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853–62—In this Article, the colours of the curves in figure 2C were reversed. This correction has been made to the online version as of Aug 7, 2015.